Eli Lilly and Company

Eli Lilly and Company will invest over $470 million to build a new pharmaceutical manufacturing facility in Durham, North Carolina, creating more than 460 jobs.

Eli Lilly announced a $400 million capital investment in its manufacturing facilities at the Lilly Technology Center campus in Indianapolis, Indiana, to increase capacity for insulin and other diabetes medicines and add about 100 highly skilled jobs.

Evonik Industries and Eli Lilly renewed a long-term agreement for Evonik to supply active pharmaceutical ingredients and intermediates for Lilly's human and veterinary drug products, with much of the supply coming from Evonik's Tippecanoe site in Indiana.

Eli Lilly announced plans to invest $850 million in its U.S. operations in 2017, including an $85 million expansion of Trulicity device assembly operations and a $140 million insulin cartridge production facility in Indianapolis.

Eli Lilly acquired a manufacturing facility in Pleasant Prairie, Wisconsin from Nexus Pharmaceuticals in 2024 and announced a $3 billion expansion to extend its global parenteral product manufacturing network. The expansion will add 750 jobs and bring total investment to $4 billion.